An interventional study of Placebo and Supplement in Joint Discomfort, Musculoskeletal Pain and Mobility Limitation, sponsored by Able Biolabs, LLC. Completed at 1 site in United States. Open to participants aged 18 Years to 75 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2026-11-16.
Sponsored by Able Biolabs, LLC · Not applicable, Interventional, and Supportive care
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 155 studies in Musculoskeletal Pain with a site in United States — 29 open to participants now, 35 under way, 1 of them phase 3. Musculoskeletal Pain · United States.
Among the 155 studies in Musculoskeletal Pain with a site in United States, this one is the 87th largest by enrollment of the 136 interventional ones that give a count, is one of 18 that started in 2026, is one of 114 with no phase, and was the 146th registered.
518 studies on the registry are indexed under Musculoskeletal Pain; 127 are open to participants now.
Browse Musculoskeletal Pain studies →29 of the 155 studies in Musculoskeletal Pain with a site in United States are open now. Recruiting first, the newest first:
University of North Carolina, Chapel Hill · Sites in United States
Ages 18+
Margaret L Gourlay, MD, MPH · Sites in United States
Ages 50–64
Stanford University · Sites in United States
Ages 18+
Children's Hospital Medical Center, Cincinnati · Sites in United States
Ages 14–26
University of Utah · Sites in United States
Ages 40–80
A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →
Of the 66 Musculoskeletal Pain studies recruiting now, 30 (45%) set no upper age limit and 30 (45%) stop at 75 or younger; 8 take children under 18; 18 take healthy volunteers.
This study: 18 Years to 75 Years · all sexes · healthy volunteers too.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
155 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 5 · Phase 2 10 · Phase 3 3 · Phase 4 6
First in 2002; this study’s year is marked. 18 started in 2026.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 40 is below the median of 69 across 373 interventional studies indexed under Musculoskeletal Pain.
Median enrollment 60 across the 136 interventional studies, 195 across the 19 observational. Of the 110 that completed or were terminated, 41 (37%) have results posted.
This tab as a report to print or save as PDF → With an account.
21 of 155 have an industry lead sponsor. The 10 most frequent:
Able Biolabs, LLC is the lead sponsor of 4 studies on the registry; none are open to participants now.
Able Biolabs, LLC has 1 study filed under Musculoskeletal Pain — fewer than ten, so there is no comparison to draw.
12 of the studies in Musculoskeletal Pain with a site in United States that are under way reach primary completion within a year, 0 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT02979574Memorial Sloan Kettering Cancer CenterPEACE: Comparing Chronic Pain Treatment Options | 2026-11 |
| NCT06867757Stanford UniversityTargeted Realtime Assessment of Chronic Pain in Youth | 2026-11 |
| NCT07393503State University of New York at BuffaloMusculoskeletal Outcomes Using Tylenol/Ibuprofen vs. Oral Steroids in New Injuries | 2027-01 |
| NCT06886906Indiana UniversityExploring the Acute and Dynamic Relationships Between Movement and Pain in Older Adults With Musculoskeletal Pain | 2027-01-01 |
| NCT06119698Massachusetts General HospitalImproving Health for Older Adults With Pain Through Engagement | 2027-04-01 |
Add all 12 to your calendar (.ics) → With an account.
Among the 155 studies in Musculoskeletal Pain with a site in United States, from their registry updates:
This tab as a report to print or save as PDF → With an account.
This randomized, double-blind, placebo-controlled study evaluates the effects of resO™ Bone and Joint Support Postbiotic on physical function, pain interference, mobility, and recovery in adults aged 18-75 years experiencing joint discomfort, stiffness, or reduced mobility.
Participants will be randomized to receive either resO™ or placebo for 4 weeks. Outcomes will be assessed using validated patient-reported outcome measures, including PROMIS Physical Function, PROMIS Pain Interference, Duke Activity Status Index (DASI), International Physical Activity Questionnaire-Short Form (IPAQ-SF), and pain numeric rating scales.
The primary objective is to evaluate whether resO™ improves physical function and reduces pain interference compared with placebo.
Joint discomfort and reduced mobility are associated with impaired physical function, pain interference, and decreased quality of life. Chronic low-grade inflammation and connective tissue degeneration contribute to limitations in daily activities and recovery.
This study evaluates resO™ Bone and Joint Support Postbiotic, a microbiome-informed supplement containing heat-inactivated Lactiplantibacillus plantarum RSB11® HI combined with glucosamine sulfate, chondroitin sulfate, methylsulfonylmethane (MSM), Boswellia serrata extract, curcumin extract, bromelain, and vitamin D3.
This is a prospective, randomized, double-blind, placebo-controlled, parallel-group study conducted remotely using electronic data capture. Approximately 40 participants aged 18-75 years with self-reported joint discomfort, stiffness, or reduced mobility will be randomized 1:1 to receive either resO™ or placebo for 4 weeks.
Primary endpoints include changes from baseline to Week 4 in:
PROMIS Physical Function T-score PROMIS Pain Interference T-score
Secondary endpoints include:
Pain intensity Numeric Rating Scale (NRS) Duke Activity Status Index (DASI) International Physical Activity Questionnaire-Short Form (IPAQ-SF) Activity limitation assessments Musculoskeletal recovery assessments Rescue medication use
Safety and tolerability will be assessed through adverse event monitoring and gastrointestinal tolerability questionnaires.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Provide voluntary signed Adults aged 18-75 years Self-reported joint discomfort, stiffness, or reduced mobility affecting daily activities In generally good health based on self-reported medical history Agree to maintain stable diet, exercise, and lifestyle patterns throughout the study Able and willing to comply with study procedures and electronic questionnaires Access to smartphone, tablet, or computer with internet access
Exclusion Criteria
Chronic inflammatory or joint disease requiring or biologic therapy Recent joint surgery or significant musculoskeletal injury within the past 3 months Current unstable use of prescription medications intended for joint pain or inflammation Regular use of joint-targeting supplements that cannot be discontinued prior to participation Known allergy or intolerance to study product ingredients Participation in another study within the past 30 days Pregnant, planning pregnancy, or breastfeeding Significant uncontrolled medical condition that may interfere with study participation or interpretation of results Inability or unwillingness to comply with study procedures
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
A condition in which the immune system attacks the body’s own tissues, such as rheumatoid arthritis, lupus, psoriasis, type 1 diabetes or inflammatory bowel disease.
Immunotherapy studies often leave out active autoimmune disease, and some name exceptions, such as thyroid disease on replacement hormone. Check the exceptions this study lists.
A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.
Read whether the line is about a condition or about medicines, and which medicines and doses it means.
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Autoimmune disease
A condition in which the immune system attacks the body’s own tissues, such as rheumatoid arthritis, lupus, psoriasis, type 1 diabetes or inflammatory bowel disease.
Immunotherapy studies often leave out active autoimmune disease, and some name exceptions, such as thyroid disease on replacement hormone. Check the exceptions this study lists.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Immunosuppression
A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.
Read whether the line is about a condition or about medicines, and which medicines and doses it means.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Investigational drug or device
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Other: Placebo
Dietary Supplement: Supplement
Inactivated supplement
Active supplement
Change From Baseline to Week 4 in PROMIS Physical Function T-score
PROMIS Physical Function Adult Short Form is a validated patient-reported outcome measure assessing physical functioning including walking, climbing stairs, bending, and carrying objects. Scores are standardized as T-scores with a population mean of 50 and standard deviation of 10. Higher scores indicate better physical function.
Time frame: Baseline and Week 4
Changes in gut microbiota composition associated with bone health
Time frame: 8 weeks
Change From Baseline to Week 4 in PROMIS Pain Interference T-score
PROMIS Pain Interference Adult Short Form is a validated patient-reported outcome measure assessing the extent to which pain interferes with daily activities, social participation, and quality of life. Scores are standardized as T-scores with a population mean of 50 and standard deviation of 10. Higher scores indicate greater pain interference.
Time frame: Baseline and Week 4
Change From Baseline to Week 4 in Pain Intensity Numeric Rating Scale (NRS) Score
Pain intensity will be assessed using an 11-point Numeric Rating Scale ranging from 0 (no pain) to 10 (worst imaginable pain).
Time frame: Baseline, weekly through Week 4, and Week 4
Change From Baseline to Week 4 in Duke Activity Status Index (DASI) Score
The Duke Activity Status Index (DASI) is a validated questionnaire assessing functional capacity and activities of daily living. Scores range from 0 to 58.2, with higher scores indicating greater functional capacity.
Time frame: Baseline and Week 4
Change From Baseline to Week 4 in International Physical Activity Questionnaire-Short Form (IPAQ-SF) MET-minutes/week
IPAQ-SF assesses physical activity including walking, moderate activity, vigorous activity, and sedentary behavior. Results are expressed as MET-minutes per week.
Time frame: Baseline and Week 4
Ran from Apr 2026 to primary completion in Jun 2026, 1 month.
Of 226 non-industry interventional studies with no phase under Musculoskeletal Pain, half reached primary completion within 13 months of starting (the median), counting those still running; a quarter within 5 and three quarters within 34. This study's 1 month is below that.
Counting every sponsor, half of 239 studies reached it within 12 months; a quarter within 5 and three quarters within 32.
Since we started tracking on Sep 25, 2026, the dates moved once, on Nov 16, 2026: primary completion May 2026 → Jun 2026 and completion May 2026 → Jun 2026.
Earlier changes are on the record history on ClinicalTrials.gov ↗
How these figures are worked out, and which studies are left out of them.
From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗
This study is completed, as verified in May 2026. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Able Biolabs, LLC